Company intelligence / Profile preview
InCarda Therapeutics
San Francisco, California, United Statesincardatherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
InCarda's lead product InRhythm (orally inhaled flecainide) has completed Phase 2 trials showing rapid conversion from atrial fibrillation to normal sinus rhythm with median conversion time of less than 15 minutes. The company started a pivotal Phase 3 RESTORE-1 trial but halted it according to recent information from September 2024. They are planning continued development with a new delivery system[6][7][10].
- Therapeutic areas
- Cardiovascular
- Modalities
- Inhaled therapiesspecifically inhaled flecainide
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on InCarda Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on InCarda Therapeutics.